Chinook pauses PhI kidney disease trial after serious adverse event

Paul Schloesser

Associate Editor

Chinook Therapeutics said it temporarily halted dosing participants in the Phase I trial of its treatment for an ultra-rare genetic kidney disease after one of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Chinook pauses PhI kidney disease trial after serious adverse event

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Chi­nook paus­es PhI kid­ney dis­ease tri­al af­ter se­ri­ous ad­verse event

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Chinook pauses PhI kidney disease trial after serious adverse event